Xingqi Eye Drops (300573) announced on the evening of May 21 that it received the Drug Registration Certificate for Bemiprost Eye Drops issued by the National Medical Products Administration (hereinafter referred to as "NMPA") on the same day.

This product is an eye drop formulation with bimeprost as the active ingredient. Two specifications have been approved: a 0.03% (0.4ml: 0.12mg) single-dose eye drop without antibacterial agents and a 0.03% (3ml: 0.9mg) multi-dose eye drop. Both specifications are indicated for lowering intraocular pressure in patients with open-angle glaucoma and ocular hypertension. The original drug already imported into China is the multi-dose product containing antibacterial agents. To date, in addition to this product, one similar single-dose generic and two multi-dose generic drugs have been approved for marketing in China.

Xingqi Eye Drops stated that due to the high-tech, high-risk, and high-value-added characteristics of pharmaceutical products, the future market sales of drugs may be affected by factors such as changes in the market environment and the implementation of bidding processes, which presents uncertainties.

Xingqi Eye Drops is a leading domestic enterprise specializing in the research, development, production, and sales of ophthalmic drugs, boasting advanced R&D technology and a broad product line. The company's products include medications to slow the progression of myopia in children, dry eye treatments, ophthalmic anti-infectives, ophthalmic anti-inflammatory/anti-infectives, mydriatics and cycloplegics, ophthalmic nonsteroidal anti-inflammatory drugs, miotics, and anti-glaucoma medications, covering more than ten subcategories of ophthalmic drugs. The company has established a comprehensive and diverse ophthalmic drug product system.

Xingqi Eye Drops achieved operating revenue of RMB 2.473 billion in 2025, a year-on-year increase of 27.24%; net profit attributable to shareholders of the listed company was RMB 696 million, a year-on-year increase of 105.84%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was RMB 697 million, a year-on-year increase of 100.56%; and basic earnings per share were RMB 2.83.

In the first quarter of 2026, Xingqi Pharmaceutical achieved operating revenue of RMB 683 million, a year-on-year increase of 27.45%; net profit attributable to shareholders of the listed company was RMB 206 million, a year-on-year increase of 41.48%; and basic earnings per share were RMB 0.84.

Since the beginning of this year, Xingqi Pharmaceuticals has made a series of important progress in research and development. For example, on the evening of February 3, Xingqi Pharmaceuticals announced that its SQ-129 vitreous sustained-release injection had completed the enrollment of the first subject in a Phase I/II clinical trial evaluating the safety, pharmacokinetic characteristics and preliminary efficacy of SQ-129 vitreous sustained-release injection in the treatment of diabetic macular edema, and officially entered the Phase I/II clinical trial.

According to an announcement by Xingqi Pharmaceutical on the evening of March 11, the company's SQ-24071 eye drops completed the enrollment of its first subject in a "single-center, randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, and pharmacokinetics of SQ-24071 eye drops in healthy participants with single/multiple doses," officially entering the clinical trial. SQ-24071 eye drops is a drug developed by the company to slow the progression of myopia. This Phase I study is a single-center, randomized, double-blind, placebo-controlled clinical trial aimed at evaluating the safety and tolerability of SQ-24071 eye drops with single/multiple doses in healthy participants, analyzing and evaluating systemic exposure, and assessing the drug's pharmacokinetic (PK) characteristics. As of the date of the announcement, no such ophthalmic formulation product is currently marketed domestically or internationally.

In its 2025 annual report, Xingqi Pharmaceuticals stated that the main structure of its newly constructed R&D center project, serving as the core physical space and strategic carrier for its future development plan, has been completed. Once operational, the new R&D center platform will empower technological innovation and achieve comprehensive research coverage across the entire ophthalmic drug supply chain.

https://www.stcn.com/article/detail/3921074.html